(8R,9S,10S,13S,14S,16R,17R)-16-fluoro-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (8R,9S,10S,13S,14S,16R,17R)-16-fluoro-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
• 化学式: C₁₉H₂₉FO₂
• 分子量: 308.4
• InChiKey: LNSIGBRLIFKJTK-AKPIMPPYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Therapeutic treatment methods
  申请人：Harbor BioSciences, Inc.

  公开号：EP2298315A1

  公开（公告）日：2011-03-23

  The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17α-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.

  本发明涉及使用化合物来改善或治疗诸如囊性纤维化、中性粒细胞减少症或其他示例性疾病。可使用的示例化合物包括 3β-羟基-17β-氨基雄甾-5-烯、3β-羟基-16α-氟-17β-氨基雄甾-5-烯、3α-羟基-16α-氟-17α-氨基雄甾-5-烯、3β-羟基-16β-氟-17β-氨基雄甾-5-烯、1α,3β-二羟基-4α-氟-雄甾-5-烯-17-酮、1α,3β,17β-三羟基-4α-氟雄甾烷-5-烯、1β,3β-二羟基-6α-溴雄甾烷-5-烯、1α-氟-3β,12α-二羟基雄甾烷-5-烯-17-酮、1α-氟-3β,4α-二羟基雄甾烷-5-烯和 4α-氟-3β,6α,17β-三羟基雄甾烷。
• Therapeutic treatment methods 2
  申请人：Reading L. Christopher

  公开号：US20050101581A1

  公开（公告）日：2005-05-12

  The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.

  本发明涉及使用化合物来改善或治疗诸如囊性纤维化、中性粒细胞减少症或其他示例性疾病。可使用的示例化合物包括 3β-羟基-17β-氨基雄甾-5-烯、3β-羟基-16α-氟-17β-氨基雄甾-5-烯、3α-羟基-16α-氟-17β-氨基雄甾-5-烯、3β-羟基-16β-氟-17β-氨基雄甾-5-烯、1α,3β-二羟基-4α-氟-雄甾-5-烯-17-酮、1α,3β,17β-三羟基-4α-氟雄甾烷-5-烯、1β,3β-二羟基-6α-溴雄甾烷-5-烯、1α-氟-3β,12α-二羟基雄甾烷-5-烯-17-酮、1α-氟-3β,4α-二羟基雄甾烷-5-烯和 4α-氟-3β,6α,17β-三羟基雄甾烷。
• Treatment screening methods
  申请人：Frincke M. James

  公开号：US20060073099A1

  公开（公告）日：2006-04-06

  The invention includes a method to identify a method to enhance survival of a subject that has been exposed to a biological insult such as an ionizing radiation dose of LD 50/30 by treating the exposed subject with a test compound an optically comparing the results to that obtained using control subjects that had been treated with 3β,17β-dihydroxyandrost-5-ene or other disclosed compounds.

  本发明包括一种方法，用于确定如何提高受到生物损伤的受试者的存活率，如电离辐射剂量为 LD 50/30 用试验化合物处理受试者，并将结果与用 3β,17β-二羟基雄甾-5-烯或其他已公开化合物处理的对照受试者的结果进行光学比较。
• THERAPEUTIC TREATMENT METHODS
  申请人：Hollis-Eden Pharmaceuticals Inc.

  公开号：EP1539183A1

  公开（公告）日：2005-06-15
• EP1539183A4
  申请人：——

  公开号：EP1539183A4

  公开（公告）日：2007-04-25